AtriCure (NASDAQ:ATRC) & SS Innovations International (NASDAQ:SSII) Head-To-Head Analysis

AtriCure (NASDAQ:ATRC) and SS Innovations International (NASDAQ:SSII) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Earnings & Valuation

This table compares AtriCure and SS Innovations International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53 million	5.41	-$11.45 million	$0.30	189.47
SS Innovations International	$42.49 million	7.83	-$12.13 million	($0.06)	-27.67

AtriCure has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

AtriCure has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, SS Innovations International has a beta of -1.52, meaning that its share price is 252% less volatile than the S&P 500.

Insider and Institutional Ownership

99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares AtriCure and SS Innovations International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	2.52%	4.01%	3.03%
SS Innovations International	-23.73%	-26.77%	-15.01%

Analyst Ratings

This is a summary of current ratings for AtriCure and SS Innovations International, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1	4	6	1	2.58
SS Innovations International	1	0	0	0	1.00

AtriCure currently has a consensus price target of $62.30, indicating a potential upside of 9.61%. SS Innovations International has a consensus price target of $7.00, indicating a potential upside of 321.69%. Given SS Innovations International’s higher probable upside, analysts plainly believe SS Innovations International is more favorable than AtriCure.

Summary

AtriCure beats SS Innovations International on 13 of the 15 factors compared between the two stocks.

About AtriCure

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.

About SS Innovations International

SS Innovations International is a medical technology company focused on developing and manufacturing surgical robotic systems. Its flagship product, the SSI Mantra, is a multi-arm platform designed to support surgeons during minimally invasive procedures. The company’s offerings include surgical instruments and related technologies, such as its SSI Mudra instruments, as well as training and support services for hospitals and clinicians. The SSI Mantra system is designed with features including a surgeon console and 3D visualization, and the company has also emphasized remote surgery and telementoring capabilities.